Inducible mutant huntingtin expression in HN10 cells reproduces Huntington's disease-like neuronal dysfunction

Molecular Neurodegeneration

Volumn 4, Issue 1, 2009, Pages

  Weiss, Andreas ^a   Roscic, Ana ^a   Paganetti, Paolo ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

EID: 60849106643     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-4-11     Document Type: Article

References (53)

1. Huntington's disease in Venezuela: neurologic features and functional decline. AB Young I Shoulson JB Penney S Starosta-Rubinstein F Gomez H Travers MA Ramos-Arroyo SR Snodgrass E Bonilla H Moreno, Neurology 1986 36 2 244 249 2935747
2. Differences in duration of Huntington's disease based on age at onset. T Foroud J Gray J Ivashina PM Conneally, J Neurol Neurosurg Psychiatry 1999 66 1 52 56 9886451
3. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. HR Group, Cell 1993 72 6 971 983 8458085
4. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. B Woodman R Butler C Landles MK Lupton J Tse E Hockly H Moffitt K Sathasivam GP Bates, Brain Res Bull 2007 72 2-3 83 97 17352931
5. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. A Lunkes KS Lindenberg L Ben-Haiem C Weber D Devys GB Landwehrmeyer JL Mandel Y Trottier, Mol Cell 2002 10 2 259 269 12191472
6. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. M Arrasate S Mitra ES Schweitzer MR Segal S Finkbeiner, Nature 2004 431 7010 805 810 15483602
7. Selective inhibitors of death in mutant huntingtin cells. H Varma C Voisine CT DeMarco E Cattaneo DC Lo AC Hart BR Stockwell, Nat Chem Biol 2007 3 2 99 100 17195849
8. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. YJ Kim Y Yi E Sapp Y Wang B Cuiffo KB Kegel ZH Qin N Aronin M DiFiglia, Proc Natl Acad Sci USA 2001 98 22 12784 12789 11675509
9. Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models. G Schilling A Klevytska AT Tebbenkamp K Juenemann J Cooper V Gonzales H Slunt M Poirer CA Ross DR Borchelt, J Neuropathol Exp Neurol 2007 66 4 313 320 17413322
10. N-terminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell model of Huntington's disease. T Ratovitski M Nakamura J D'Ambola E Chighladze Y Liang W Wang R Graham MR Hayden DR Borchelt RR Hirschhorn, Cell Cycle 2007 6 23 2970 2981 18156806
11. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. A Weiss C Klein B Woodman K Sathasivam M Bibel E Regulier GP Bates P Paganetti, J Neurochem 2008 104 3 846 858 17986219
12. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. A Kuhn DR Goldstein A Hodges AD Strand T Sengstag C Kooperberg K Becanovic MA Pouladi K Sathasivam JH Cha, Hum Mol Genet 2007 16 15 1845 1861 17519223
13. Global changes to the ubiquitin system in Huntington's disease. EJ Bennett TA Shaler B Woodman KY Ryu TS Zaitseva CH Becker GP Bates H Schulman RR Kopito, Nature 2007 448 7154 704 708 17687326
14. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. E Trushina RB Dyer JD Badger 2nd D Ure L Eide DD Tran BT Vrieze V Legendre-Guillemin PS McPherson BS Mandavilli, Mol Cell Biol 2004 24 18 8195 8209 15340079
15. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. S Gunawardena LS Her RG Brusch RA Laymon IR Niesman B Gordesky-Gold L Sintasath NM Bonini LS Goldstein, Neuron 2003 40 1 25 40 14527431
16. Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. A Solans A Zambrano M Rodriguez A Barrientos, Hum Mol Genet 2006 15 20 3063 3081 16968735
17. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. AW Dunah H Jeong A Griffin YM Kim DG Standaert SM Hersch MM Mouradian AB Young N Tanese D Krainc, Science 2002 296 5576 2238 2243 11988536
18. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. A Wyttenbach J Swartz H Kita T Thykjaer J Carmichael J Bradley R Brown M Maxwell A Schapira TF Orntoft, Hum Mol Genet 2001 10 17 1829 1845 11532992
19. Instability of the CAG repeat in immortalized fibroblast cell cultures from Huntington's disease transgenic mice. K Manley J Pugh A Messer, Brain Res 1999 835 1 74 79 10448198
20. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. A Sawa GW Wiegand J Cooper RL Margolis AH Sharp JF Lawler Jr JT Greenamyre SH Snyder CA Ross, Nat Med 1999 5 10 1194 1198 10502825
21. Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments. M Coufal MM Maxwell DE Russel AM Amore SM Altmann ZR Hollingsworth AB Young DE Housman AG Kazantsev, J Biomol Screen 2007 12 3 351 360 17379859
22. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. H Li SH Li H Johnston PF Shelbourne XJ Li, Nat Genet 2000 25 4 385 389 10932179
23. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. F Saudou S Finkbeiner D Devys ME Greenberg, Cell 1998 95 1 55 66 9778247
24. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. F Trettel D Rigamonti P Hilditch-Maguire VC Wheeler AH Sharp F Persichetti E Cattaneo ME MacDonald, Hum Mol Genet 2000 9 19 2799 2809 11092756
25. Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Q Ruan M Lesort ME MacDonald GV Johnson, Hum Mol Genet 2004 13 7 669 681 14962977
26. Immortalized young adult neurons from the septal region: generation and characterization. HJ Lee DN Hammond TH Large BH Wainer, Brain Res Dev Brain Res 1990 52 1-2 219 228 2331789
27. Down-regulation of the neurotrophin receptor TrkB following ligand binding. Evidence for an involvement of the proteasome and differential regulation of TrkA and TrkB. MT Sommerfeld R Schweigreiter YA Barde E Hoppe, J Biol Chem 2000 275 12 8982 8990 10722747
28. Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. GJ Brewer JR Torricelli EK Evege PJ Price, J Neurosci Res 1993 35 5 567 576 8377226
29. Inducible phosphorylation of NF-kappa B p65 at serine 468 by T cell costimulation is mediated by IKK epsilon. I Mattioli H Geng A Sebald M Hodel C Bucher M Kracht ML Schmitz, J Biol Chem 2006 281 10 6175 6183 16407239
30. Measuring nitric oxide and superoxide: rate constants for aconitase reactivity. A Hausladen I Fridovich, Methods Enzymol 1996 269 37 41 8791635
31. Aconitase is a sensitive and critical target of oxygen poisoning in cultured mammalian cells and in rat lungs. PR Gardner DD Nguyen CW White, Proc Natl Acad Sci USA 1994 91 25 12248 12252 7991614
32. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. M DiFiglia E Sapp KO Chase SW Davies GP Bates JP Vonsattel N Aronin, Science 1997 277 5334 1990 1993 9302293
33. Pyramidal cell loss in motor cortices in Huntington's disease. V Macdonald G Halliday, Neurobiol Dis 2002 10 3 378 386 12270698
34. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. HD Rosas WJ Koroshetz YI Chen C Skeuse M Vangel ME Cudkowicz K Caplan K Marek LJ Seidman N Makris, Neurology 2003 60 10 1615 1620 12771251
35. In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. C Fennema-Notestine SL Archibald MW Jacobson J Corey-Bloom JS Paulsen GM Peavy AC Gamst JM Hamilton DP Salmon TL Jernigan, Neurology 2004 63 6 989 995 15452288
36. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. P Puigserver BM Spiegelman, Endocr Rev 2003 24 1 78 90 12588810
37. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. P Weydt VV Pineda AE Torrence RT Libby TF Satterfield ER Lazarowski ML Gilbert GJ Morton TK Bammler AD Strand, Cell Metab 2006 4 5 349 362 17055784
38. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. L Cui H Jeong F Borovecki CN Parkhurst N Tanese D Krainc, Cell 2006 127 1 59 69 17018277
39. Biological abnormalities of peripheral A(2A) receptors in a large representation of polyglutamine disorders and Huntington's disease stages. K Varani AC Bachoud-Levi C Mariotti A Tarditi MP Abbracchio V Gasperi PA Borea G Dolbeau C Gellera A Solari, Neurobiol Dis 2007 27 1 36 43 17512749
40. Adenosine and its receptors: multiple modulatory functions and potential therapeutic targets for neurologic disease. EE Benarroch, Neurology 2008 70 3 231 236 18195269
41. Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. L Djousse B Knowlton MR Hayden EW Almqvist RR Brinkman CA Ross RL Margolis A Rosenblatt A Durr C Dode, Neurogenetics 2004 5 2 109 114 15029481
42. Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. H Runne A Kuhn EJ Wild W Pratyaksha M Kristiansen JD Isaacs E Regulier M Delorenzi SJ Tabrizi R Luthi-Carter, Proc Natl Acad Sci USA 2007 104 36 14424 14429 17724341
43. Oxidative damage during aging targets mitochondrial aconitase. LJ Yan RL Levine RS Sohal, Proc Natl Acad Sci USA 1997 94 21 11168 11172 9326580
44. Redox-dependent modulation of aconitase activity in intact mitochondria. AL Bulteau M Ikeda-Saito LI Szweda, Biochemistry 2003 42 50 14846 14855 14674759
45. Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. D Rigamonti S Sipione D Goffredo C Zuccato E Fossale E Cattaneo, J Biol Chem 2001 276 18 14545 14548 11278258
46. Complex I defect in muscle from patients with Huntington's disease. J Arenas Y Campos R Ribacoba MA Martin JC Rubio P Ablanedo A Cabello, Ann Neurol 1998 43 3 397 400 9506560
47. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. R Lodi AH Schapira D Manners P Styles NW Wood DJ Taylor TT Warner, Ann Neurol 2000 48 1 72 76 10894218
48. Formation of polyglutamine inclusions in non-CNS tissue. K Sathasivam C Hobbs M Turmaine L Mangiarini A Mahal F Bertaux EE Wanker P Doherty SW Davies GP Bates, Hum Mol Genet 1999 8 5 813 822 10196370
49. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. E Scherzinger A Sittler K Schweiger V Heiser R Lurz R Hasenbank GP Bates H Lehrach EE Wanker, Proc Natl Acad Sci USA 1999 96 8 4604 4609 10200309
50. Wild-type huntingtin protects from apoptosis upstream of caspase-3. D Rigamonti JH Bauer C De-Fraja L Conti S Sipione C Sciorati E Clementi A Hackam MR Hayden Y Li, J Neurosci 2000 20 10 3705 3713 10804212
51. Wild-type huntingtin protects neurons from excitotoxicity. BR Leavitt JM van Raamsdonk J Shehadeh H Fernandes Z Murphy RK Graham CL Wellington LA Raymond MR Hayden, J Neurochem 2006 96 4 1121 1129 16417581
52. Huntingtin contains a highly conserved nuclear export signal. J Xia DH Lee J Taylor M Vandelft R Truant, Hum Mol Genet 2003 12 12 1393 1403 12783847
53. Huntington's Disease. GP Bates P Harper L Jones, Oxford: Oxford University Press 3 2002